This unexpected increase in cell size was specific to CD14+ monocytes, as we next compared FSC statistics in CD14 and CD3 bifurcate gates and found no differences between T2D and ND COVID‐19 patients in CD14−, CD3+ nor CD3− cells (Appendix Fig S2B). This evidence concerns the gene CD14 and COVID-19.